Prothrombin complex concentrate

Dennis J Cada; Terri L Levien; Danial E Baker

doi:10.1310/hpj4811-951

Prothrombin complex concentrate

Hosp Pharm. 2013 Dec;48(11):951-7. doi: 10.1310/hpj4811-951.

Authors

Dennis J Cada¹, Terri L Levien², Danial E Baker³

Affiliations

¹ Founder and Contributing Editor, The Formulary.
² Clinical Associate Professor of Pharmacotherapy, Drug Information Center, Washington State University, Spokane, Washington.
³ Director, Drug Information Center, and Professor of Pharmacy Practice, College of Pharmacy, Washington State University Spokane, PO Box 1495, Spokane, Washington 99210-1495. The authors indicate no relationships that could be perceived as a conflict of interest .

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are sent in print and are also available on-line. Monographs can be customized to meet the needs of a facility. A drug class review is now published monthly with The Formulary Monograph Service. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, call The Formulary at 800-322-4349. The December 2013 monograph topics are vortioxetine, mechlorethamine gel, brimonidine tartrate topical gel, obinutuzumab, and miltefosine. The DUE/MUE is on vortioxetine.